Bioavailability and transport of peptides and peptide drugs into the brain

Richard D. Egleton, Thomas P Davis

Research output: Contribution to journalArticle

146 Citations (Scopus)

Abstract

Rational drug design and the targeting of specific organs has become a reality in modern drug development, with the emergence of molecular biology and receptor chemistry as powerful tools for the pharmacologist. A greater understanding of peptide function as one of the major extracellular message systems has made neuropeptides an important target in neuropharmaceutical drug design. The major obstacle to targeting the brain with therapeutics is the presence of the blood-brain barrier (BBB), which controls the concentration and entry of solutes into the central nervous system. Peptides are generally polar in nature, do not easily cross the blood-brain barrier by diffusion, and except for a small number do not have specific transport systems. Peptides can also undergo metabolic deactivation by peptidases of the blood, brain and the endothelial cells that comprise the BBB. In this review, we discuss a number of the recent strategies which have been used to promote peptide stability and peptide entry into the brain. In addition, we approach the subject of targeting specific transport systems that can be found on the brain endothelial cells, and describe the limitations of the methodologies that are currently used to study brain entry of neuropharmaceuticals.

Original languageEnglish (US)
Pages (from-to)1431-1439
Number of pages9
JournalPeptides
Volume18
Issue number9
DOIs
StatePublished - 1997

Fingerprint

Biological Availability
Brain
Peptides
Blood-Brain Barrier
Pharmaceutical Preparations
Drug Design
Endothelial cells
Endothelial Cells
Molecular biology
Neurology
Drug Delivery Systems
Neuropeptides
Molecular Biology
Blood
Peptide Hydrolases
Central Nervous System
Therapeutics

Keywords

  • Blood-brain barrier
  • Peptides
  • Transport systems

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Bioavailability and transport of peptides and peptide drugs into the brain. / Egleton, Richard D.; Davis, Thomas P.

In: Peptides, Vol. 18, No. 9, 1997, p. 1431-1439.

Research output: Contribution to journalArticle

Egleton, Richard D. ; Davis, Thomas P. / Bioavailability and transport of peptides and peptide drugs into the brain. In: Peptides. 1997 ; Vol. 18, No. 9. pp. 1431-1439.
@article{e10204b6c47346bf942759b48872b869,
title = "Bioavailability and transport of peptides and peptide drugs into the brain",
abstract = "Rational drug design and the targeting of specific organs has become a reality in modern drug development, with the emergence of molecular biology and receptor chemistry as powerful tools for the pharmacologist. A greater understanding of peptide function as one of the major extracellular message systems has made neuropeptides an important target in neuropharmaceutical drug design. The major obstacle to targeting the brain with therapeutics is the presence of the blood-brain barrier (BBB), which controls the concentration and entry of solutes into the central nervous system. Peptides are generally polar in nature, do not easily cross the blood-brain barrier by diffusion, and except for a small number do not have specific transport systems. Peptides can also undergo metabolic deactivation by peptidases of the blood, brain and the endothelial cells that comprise the BBB. In this review, we discuss a number of the recent strategies which have been used to promote peptide stability and peptide entry into the brain. In addition, we approach the subject of targeting specific transport systems that can be found on the brain endothelial cells, and describe the limitations of the methodologies that are currently used to study brain entry of neuropharmaceuticals.",
keywords = "Blood-brain barrier, Peptides, Transport systems",
author = "Egleton, {Richard D.} and Davis, {Thomas P}",
year = "1997",
doi = "10.1016/S0196-9781(97)00242-8",
language = "English (US)",
volume = "18",
pages = "1431--1439",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Bioavailability and transport of peptides and peptide drugs into the brain

AU - Egleton, Richard D.

AU - Davis, Thomas P

PY - 1997

Y1 - 1997

N2 - Rational drug design and the targeting of specific organs has become a reality in modern drug development, with the emergence of molecular biology and receptor chemistry as powerful tools for the pharmacologist. A greater understanding of peptide function as one of the major extracellular message systems has made neuropeptides an important target in neuropharmaceutical drug design. The major obstacle to targeting the brain with therapeutics is the presence of the blood-brain barrier (BBB), which controls the concentration and entry of solutes into the central nervous system. Peptides are generally polar in nature, do not easily cross the blood-brain barrier by diffusion, and except for a small number do not have specific transport systems. Peptides can also undergo metabolic deactivation by peptidases of the blood, brain and the endothelial cells that comprise the BBB. In this review, we discuss a number of the recent strategies which have been used to promote peptide stability and peptide entry into the brain. In addition, we approach the subject of targeting specific transport systems that can be found on the brain endothelial cells, and describe the limitations of the methodologies that are currently used to study brain entry of neuropharmaceuticals.

AB - Rational drug design and the targeting of specific organs has become a reality in modern drug development, with the emergence of molecular biology and receptor chemistry as powerful tools for the pharmacologist. A greater understanding of peptide function as one of the major extracellular message systems has made neuropeptides an important target in neuropharmaceutical drug design. The major obstacle to targeting the brain with therapeutics is the presence of the blood-brain barrier (BBB), which controls the concentration and entry of solutes into the central nervous system. Peptides are generally polar in nature, do not easily cross the blood-brain barrier by diffusion, and except for a small number do not have specific transport systems. Peptides can also undergo metabolic deactivation by peptidases of the blood, brain and the endothelial cells that comprise the BBB. In this review, we discuss a number of the recent strategies which have been used to promote peptide stability and peptide entry into the brain. In addition, we approach the subject of targeting specific transport systems that can be found on the brain endothelial cells, and describe the limitations of the methodologies that are currently used to study brain entry of neuropharmaceuticals.

KW - Blood-brain barrier

KW - Peptides

KW - Transport systems

UR - http://www.scopus.com/inward/record.url?scp=0030726198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030726198&partnerID=8YFLogxK

U2 - 10.1016/S0196-9781(97)00242-8

DO - 10.1016/S0196-9781(97)00242-8

M3 - Article

C2 - 9392847

AN - SCOPUS:0030726198

VL - 18

SP - 1431

EP - 1439

JO - Peptides

JF - Peptides

SN - 0196-9781

IS - 9

ER -